Neil Minton

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Ludwig Kappos, Krzysztof Selmaj, Amit Bar‐Or et al. · The Lancet Neurology · 2019 · 276 citations

Clinical Trials, Treatment Option, Pharmacotherapy +5

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Jeffrey A. Cohen, Krzysztof Selmaj, Amit Bar‐Or et al. · The Lancet Neurology · 2019 · 270 citations

Neurological Progress, Clinical Trials, Clinical Neurology +6

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Brian G. Feagan, William J. Sandborn, Silvio Danese et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 135 citations

Ozanimod Induction Therapy, Gastroenterology, Clinical Gastroenterology +5

Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis

Evan S. Dellon, Margaret H. Collins, Marc E. Rothenberg et al. · Clinical Gastroenterology and Hepatology · 2020 · 95 citations · Full text

Infections in patients diagnosed with multiple sclerosis: A multi-database study

Rebecca Persson, S. Lee, Marianne Ulcickas Yood et al. · Multiple Sclerosis and Related Disorders · 2020 · 85 citations

Disease Diagnosis, Neurological Disorder, Healthcare-associated Infection +9